Schizophrenia Drugs Market (Drug Class: First Generation Drugs, Second Generation Drugs, and Third Generation Drugs; Route of Administration: Oral and Injectable) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022 - 2030

Description

Companies Increase Focus on Second-generation Drugs with Polypharmacology Approach

Several doctors and healthcare providers are adopting the methods of polypharmacology to develop new drugs for mental disorders. These methods are providing better outcomes in patients as compared to single-target drugs in the schizophrenia drugs market.

Likewise, multi-target drugs are emerging as an effective alternative to treat polygenic diseases, including schizophrenia. As such, the second-generation drugs market is estimated to reach ~US$ 11.1 billion by the year 2027; the highest amongst all drug classes in the schizophrenia drugs landscape. These second-generation drugs, i.e. atypical antipsychotics, target a number of aminergic G-protein coupled receptors (GPCRs) to treat complex pathomechanisms of schizophrenia.

Pharmaceutical companies are increasing research & development related to the schizophrenia drugs market to develop drugs that are beyond the dopaminergic hypothesis of schizophrenia and beyond monoamine G protein coupled receptors (GPCRs). They are increasing their production capacities of dopamine antagonists and drugs meant to effectively control the symptoms of schizophrenia and improve patient quality of life. Manufacturers in the schizophrenia drugs market are also turning towards other second-generation antipsychotics, such as serotonin and histamine, to prevent amphetamine-induced behavioral changes in patients.

High-content Single-cell Screenings Serve as a Strategic Alternative

There is the growing need for improved schizophrenia drugs, as psychiatric disorders lead to disorders of the whole body. That is why, healthcare companies are innovating on live cellular function as a model to treat schizophrenia. Manufacturers in the schizophrenia drugs market are using high-content single-cell screenings to develop efficacious compounds for new schizophrenia drugs. This drug 'repurposing' strategy serves as a cost-effective and time-saving alternative for the development of new schizophrenia drugs that can be supplied to small-scale clinics and other healthcare providers.

The live cellular function model helps manufacturers develop new potential drugs at competitive costs, and acts as an efficient alternative to develop the drugs in a significantly less amount of time. The high-content single-cell screening process helps companies test existing psychiatric treatments on patient blood cells and predict the effectiveness of the new schizophrenia drug, depending upon the health condition of each individual.

This first-of-its-kind process will help healthcare companies overcome the limitations of first-line treatments, as these treatments have been performing poorly in most patients.

Study of Live Blood Cells Gives Rise to Potential Schizophrenia Drugs

One of the major challenges that restricts healthcare companies from developing novel drugs for the schizophrenia drugs market is the lack of sample-based tests. Since doctors cannot take brain tissue samples from patients like they do in a biopsy on a cancer tumor elsewhere in the body, it is challenging for researchers to study the root causes of schizophrenia. This becomes a hurdle for doctors and researchers as to what to target in order to design novel neuropsychiatric drugs. As such, healthcare companies are collaborating with doctors and researchers to study the live blood cells of patients with mental health disorders. These blood cells help researchers identify potential targets for drug discovery.

Companies are increasing focus on the study of human blood cells, as these cells are closely associated with the central nervous system. This makes blood cells an ideal environment to test potential new drugs.

Analysts’ Viewpoint

The schizophrenia drugs market is expected to grow the fastest in Asia Pacific on an account of the demand for less-invasive oral drugs that are anticipated to reach ~US$ 10.8 billion by 2027. Healthcare companies are increasing research on primary cells from patients to gain high success rates in the discovery of effective drugs. They are also innovating on antipsychotic drugs, as these drugs provide a range of tools to explore brain function in health and mental disorders. However, antipsychotic drugs have a high risk of disrupting the extrapyramidal function in patients. Also, these drugs do not have enough clinical evidence to prove their effectiveness in the development of new compounds in drugs.

As such, healthcare companies are increasing research & development to closely understand the effects of antipsychotic drugs on the central dopamine homeostasis of patients. Companies operating in the schizophrenia drugs market should focus on new models of preventive treatments of schizophrenia, such as the animal model and stem cell technology, for improved schizophrenia drug screenings.

Schizophrenia Drugs Market: Overview

Rise in the prevalence of schizophrenia, approvals for additional indications, and launch of new schizophrenia drugs are driving the schizophrenia drugs market.

The number of patients that are suffering from schizophrenia has been increasing across the world. Moreover, rise in the launch of new schizophrenia drugs in various countries is fueling the growth of the global schizophrenia market.

These factors are estimated to boost the global schizophrenia drugs market during the forecast period. The schizophrenia drugs market was valued at ~US$ 11.2 Bn in 2018, and is projected to reach ~US$ 15.5 Bn by 2027, expanding at a CAGR of ~4% from 2022 to 2030.

Schizophrenia Drugs Market: Key Trends

The market for schizophrenia drugs is an established market, owing to the high demand for schizophrenia drugs in developed as well as developing countries. Additionally, leading market players in the schizophrenia drugs market are engaged in the development of innovative products.

Based on drug class, the global schizophrenia drugs market has been categorized into first generation drugs, second generation drugs, and third generation drugs. The second generation drugs segment held a major share of the global schizophrenia drugs market in 2018, owing to their low risk of neurological side effects as compared to first generation of schizophrenia drugs.

In terms of route of administration, the global schizophrenia drugs market has been segregated into oral and injectable. The oral segment dominated the global schizophrenia drugs market, owing to easy accessibility to oral drugs, their non-invasive nature, and high preference by patients.

The number of people affected by depression has been rising all across the world. According to the WHO, more than 300 million people suffer from depression and over 800,000 people commit suicide every year. Depression is the second leading cause of death in 15–29 year olds.

Increase in the number of launches of new schizophrenia drugs in various countries is fueling the global schizophrenia drugs market.

In 2015, Otsuka Holdings Co., Ltd. announced the launch of Rexulti in the U.S. In April 2017, the drug was also launched in Canada. 

Schizophrenia Drugs Market: Competition

The report provides the company profiles that includes key information about the major players in the schizophrenia drugs market.

Each of these players have been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segment, and recent developments.

The schizophrenia drugs market is highly consolidated, owing to a small number of market players selling approved drugs for schizophrenia.

Janssen Global Services, LLC (Johnson & Johnson), ALLERGAN, Pfizer Inc., and Otsuka Holdings Co., Ltd. are major players operating in the global schizophrenia drugs market. 

FDA Approval and Product Expansion

In January 2018, Otsuka Pharmaceutical Co., Ltd. announced that it received regulatory approval for the manufacture and sales of Rexulti tablets (generic name - brexpiprazole) in Japan. Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and as an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors.

In January 2018, Janssen Global Services, LLC received FDA approval for INVEGA SUSTENNA (paliperidone palmitate), a once-monthly schizophrenia treatment drug. This is the first and only antipsychotic drug to have U.S. Food and Drug Administration (FDA) approval.

In November 2017, ALLERGAN received FDA approval for use of VRAYLAR (cariprazine) for the treatment of schizophrenia. VRAYLAR is an oral, once-daily atypical antipsychotic drug approved for the acute treatment of adult patients with manic or mixed episodes associated with bipolar disorder, with a recommended dose range of 3 to 6 mg/day, and for the treatment of schizophrenia in adults, with a recommended dose range of 1.5 to 6 mg/day. 

Mergers & Acquisitions to Strengthen Market Position

In February 2015, Pfizer, Inc. and Hospira, Inc. (a leading player in infusion technologies and injectable drugs) signed a merger agreement. Under the agreement, Pfizer would acquire Hospira for a total transaction value of ~US$ 17 Bn. This complementary merger would help in expanding the company’s portfolio of sterile injectable pharmaceuticals and biosimilars.

Key Questions Answered in the Global Schizophrenia Drugs Market Report

  • How does the development of schizophrenia drugs provide scope of growth in the market?
  • How are alliances and partnerships between players widening the scope of new lines of treatment for schizophrenia?
  • What are the revenue share projections of key segments under various criteria in the global market during the forecast period?
  • Which segment is likely to register leading revenue until the end of the forecast period?
  • How is the evolving healthcare system in developing countries of Asia Pacific making an impact on the overall market?

Global Schizophrenia Drugs Market – Segmentation

Drug Class

  • First Generation Drugs
  • Second Generation Drugs
  • Third Generation Drugs

Route of Administration

  • Injectable
  • Oral

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Schizophrenia Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Schizophrenia Drugs Introduction

        4.1.2. Market Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Schizophrenia Drugs Market Analysis and Forecast, 2017–2027

        4.4.1. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast

5. Key Insights

    5.1. Pipeline Analysis: Schizophrenia Drugs

    5.2. Value Chain Analysis

    5.3. Global Schizophrenia Drugs Sales Analysis, 2017–2027

6. Global Schizophrenia Drugs Market Analysis and Forecast, by Drug Class 

    6.1. Introduction & Definitions

    6.2. Key Findings / Developments

    6.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        6.3.1. First Generation Drugs

        6.3.2. Second Generation Drugs

        6.3.3. Third Generation Drugs

    6.4. Global Schizophrenia Drugs Market Attractiveness, by Drug Class 

7. Global Schizophrenia Drugs Market Analysis and Forecast, by Route of Administration 

    7.1. Introduction & Definitions

    7.2. Key Findings / Developments

    7.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

        7.3.1. Injectable

        7.3.2. Oral

    7.4. Global Schizophrenia Drugs Market Attractiveness, by Route of Administration 

8. Global Schizophrenia Drugs Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Global Schizophrenia Drugs Market Attractiveness, by Region

9. North America Schizophrenia Drugs Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        9.2.1. First Generation Drugs

        9.2.2. Second Generation Drugs

        9.2.3. Third Generation Drugs

    9.3. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

        9.3.1. Injectable

        9.3.2. Oral

    9.4. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Schizophrenia Drugs Market Attractiveness Analysis 

        9.5.1. By Drug Class 

        9.5.2. By Route of Administration 

        9.5.3. By Country

10. Europe Schizophrenia Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        10.2.1. First Generation Drugs

        10.2.2. Second Generation Drugs

        10.2.3. Third Generation Drugs

    10.3. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

        10.3.1. Injectable

        10.3.2. Oral

    10.4. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Italy

        10.4.5. Spain

        10.4.6. Rest of Europe

    10.5. Europe Schizophrenia Drugs Market Attractiveness Analysis 

        10.5.1. By Drug Class 

        10.5.2. By Route of Administration 

        10.5.3. By Country/Sub-region

11. Asia Pacific Schizophrenia Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        11.2.1. First Generation Drugs

        11.2.2. Second Generation Drugs

        11.2.3. Third Generation Drugs

    11.3. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

        11.3.1. Injectable

        11.3.2. Oral

    11.4. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. India

        11.4.3. Japan

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis 

        11.5.1. By Drug Class 

        11.5.2. By Route of Administration 

        11.5.3. By Country/Sub-region

12. Latin America Schizophrenia Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        12.2.1. First Generation Drugs

        12.2.2. Second Generation Drugs

        12.2.3. Third Generation Drugs

    12.3. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

        12.3.1. Injectable

        12.3.2. Oral

    12.4. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Schizophrenia Drugs Market Attractiveness Analysis 

        12.5.1. By Drug Class 

        12.5.2. By Route of Administration 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Schizophrenia Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

        13.2.1. First Generation Drugs

        13.2.2. Second Generation Drugs

        13.2.3. Third Generation Drugs

    13.3. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027

        13.3.1. Injectable

        13.3.2. Oral

    13.4. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC 

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis 

        13.5.1. By Drug Class 

        13.5.2. By Route of Administration 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Global Schizophrenia Drugs Market Share Analysis, by Company (2018)

    14.2. Company Profiles

        14.2.1. Allergan

            14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.1.2. Financial Overview

            14.2.1.3. Product Portfolio

            14.2.1.4. SWOT Analysis 

            14.2.1.5. Strategic Overview

        14.2.2. Otsuka Holdings Co., Ltd

            14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.2.2. Financial Overview

            14.2.2.3. Product Portfolio

            14.2.2.4. SWOT Analysis 

            14.2.2.5. Strategic Overview

        14.2.3. Janssen Pharmaceutica (Johnson & Johnson)

            14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.3.2. Financial Overview

            14.2.3.3. Product Portfolio

            14.2.3.4. SWOT Analysis 

            14.2.3.5. Strategic Overview

        14.2.4. Pfizer Inc.

            14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.4.2. Financial Overview

            14.2.4.3. Product Portfolio

            14.2.4.4. SWOT Analysis 

            14.2.4.5. Strategic Overview

        14.2.5. Maynepharma

            14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.5.2. Financial Overview

            14.2.5.3. Product Portfolio

            14.2.5.4. SWOT Analysis 

            14.2.5.5. Strategic Overview

        14.2.6. Vanda Pharmaceuticals Inc.

            14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.6.2. Financial Overview

            14.2.6.3. Product Portfolio

            14.2.6.4. SWOT Analysis 

            14.2.6.5. Strategic Overview

        14.2.7. Sumitomo Dainippon Pharma

            14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.7.2. Financial Overview

            14.2.7.3. Product Portfolio

            14.2.7.4. SWOT Analysis 

            14.2.7.5. Strategic Overview

        14.2.8. Eli Lilly & Co.

            14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.8.2. Financial Overview

            14.2.8.3. Product Portfolio

            14.2.8.4. SWOT Analysis 

            14.2.8.5. Strategic Overview

        14.2.9. AstraZeneca Plc

            14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.9.2. Financial Overview

            14.2.9.3. Product Portfolio

            14.2.9.4. SWOT Analysis 

            14.2.9.5. Strategic Overview

Choose License Type

Checkout Inquiry Sample